Journey Medical

AZ - ScottsdaleBiotechnology1 H-1B visas (FY2023)

Focus: Journey Medical is a dermatology-focused biotech company headquartered in Scottsdale, Arizona, generating revenue primarily from topical and oral skin treatments. The company operates a portfolio of FDA-approved dermatological products with 73% revenue concentration in QBREXZA (glycopyrronium), a hyperhidrosis treatment.

Dermatology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Open Jobs

About Journey Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Journey Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Late-stage

5 Phase 3+

LOE Risk

1 imminent

XIMINO

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

QBREXZA

Hyperhidrosis

$2M

Peak6.6yr

Flagship product driving 73% of company revenue with extended exclusivity through 2033; core to financial stability.

Help build intelligence for Journey Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Watch Out For

Extreme revenue concentration (73% from single product) and modest total portfolio sales ($2.6M across all Part D products) suggest limited scale and restructuring vulnerability
Near-term patent cliffs: XIMINO expires April 2027 and ZILXI expires October 2030, creating downside risk before pipeline catalysts mature
Zero active job postings and missing employee/funding data raise transparency concerns about organizational size, hiring velocity, and financial stability

Pipeline & Clinical Trials

Novel severity grading system of stoma-related complication in cancer patients

Complication,Postoperative

N/A

DFD-29

Pharmacokinetics

Phase 1

Clinical Trials (1)

NCT05452785A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects

Phase 1

Minocycline hydrochloride capsules

Rosacea

Phase 1

Clinical Trials (1)

NCT05597462Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

Phase 1

Topical Minocycline Foam FXFM244

Confluent and Reticulated Papillomatosis (CARP)

Phase 1

Clinical Trials (1)

NCT07462702Topical Minocycline for CARP

Phase 1

Glycopyrronium cloth, 2.4%

Palmar Hyperhidrosis

Phase 2

Clinical Trials (1)

NCT03880266A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

Phase 2

Dose 1 of glycopyrrolate, 2.0% QD

Hyperhidrosis

Phase 2

Clinical Trials (1)

NCT02129660Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

Phase 2

glycopyrrolate, 1.0%

Hyperhidrosis

Phase 2

Clinical Trials (1)

NCT02016885A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

Phase 2

Glycopyrronium Topical Wipes

Hyperhidrosis

Phase 3

Clinical Trials (1)

NCT02553798Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Phase 3

DFD-29

Papulopustular Rosacea

Phase 3

Clinical Trials (1)

NCT05296629A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

Phase 3

glycopyrronium Topical Wipes

Hyperhidrosis

Phase 3

Clinical Trials (1)

NCT02530281Study of Glycopyrronium in Axillary Hyperhydrosis

Phase 3

glycopyrronium Topical Wipes

Hyperhidrosis

Phase 3

Clinical Trials (1)

NCT02530294Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Phase 3

DFD-29

Papulopustular Rosacea

Phase 3

Clinical Trials (1)

NCT05343455A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

Phase 3

Interview Prep Quick Facts

Portfolio: 9 approved products, 11 clinical trials

Top TAs: Dermatology, Neurology, Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Growth1 (11%)

Peak3 (33%)

LOE Approaching5 (56%)

9 total products

Therapeutic Area Focus

2 marketed3 pipeline

3 marketed

3 marketed

3 marketed

3 marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

12.1 Mechanism of Action The mechanism of action of EMROSI for the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of EMROSI for the treatment of rosacea are unknown. 12.3 Pharmacokinetics EMROSI is not bioequivalent to any other minocycline products. The pharmacokinetics of minocycline following administration of EMROSI was investigated in two studies that enrolled 32 healthy, adult subjects. In Study 1, the plasma pharmacokinetic parameters for EMROSI following single dose administration under fasting and fed states are presented in . Table 1: Plasma Pharmacokinetic Parameters [Mean (%CV)] for EMROSI (40 mg) N C max (ng/mL) T max * (hr) AUC inf (ng.hr/mL) t 1/2 (hr) EMROSI (Fasting) 23 243.9 (37.3) 1.50 (1.00 – 4.17) 3933.6 (31.2) 14.67 (26.7) EMROSI (Fed) 23 225.0 (16.7) 4.50 (3.00 – 8.00) 4404.1 (21.0) 14.93 (21.5) Note: * Median (Range) In Study 2, minocycline plasma PK following EMROSI single (Day 1) and after repeated (Day 21) once daily administrations in eight (8) subjects were found to be similar with overlapping ranges. The mean C max was 382.83 ng/mL versus 337.74 ng/mL and AUC 0-24 was 3549.64 ng*hr/mL versus 3957.62 ng*hr/mL, respectively on Day 1 versus Day 21. Absorption: In Study 1, the median plasma T max of minocycline from EMROSI was 1.50 hours (1.00 - 4.17). In Study 2, the median plasma T max values of minocycline from EMROSI on Day 1 and Day 21 were 1.75 and 1.5 hours, respectively. Effect of Food: Following administration of EMROSI with a high-fat meal (1011 Kcal, 53% fat), T max was delayed by approximately 3 hours. The high fat meal did not impact the C max however, the AUC inf was increased by 15.26% ( ) [see ]. Distribution: Minocycline is lipid soluble and distributes into the skin and sebum. In Study 1, the mean apparent volume of distribution (Vz/F) values of minocycline following oral administration of EMROSI at fasting and fed condition were 229.61 (±67.83) L and 199.83 (±43.71) L, respectively. Elimination: The mean apparent elimination half-life (t ½ ) of minocycline from EMROSI was approximately 15 hours independent of fasting and fed dosing condition.

Journey Medical

About Journey Medical

Why Work Here

Key Products

Watch Out For

Products & Portfolio (5)

Key Products by Revenue

Other Products (2)

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship